In recent years, significant changes have occurred in metastatic hormone-sensitive prostate
cancer (mHSPC) management, where docetaxel and new androgen receptor pathway …

In recent years, the advanced knowledge of clinical, biological and molecular features of
prostate cancer have led to the introduction of new drugs and have allowed the relocation of …

Simple Summary In this review, we summarize the risk factors of prostate cancer (PCa),
mechanism of PCa induced bone metastasis, current treatments for PCa induced bone …

Background The outcomes of metastatic hormone-sensitive prostate cancer (mHSPC) have
significantly improved through treatment intensification, yet Black representation in those …

Objective To investigate the clinical significance of the expression of the stemness marker
CD133 in circulating tumor cells of newly diagnosed metastatic castration‐sensitive prostate …

Objective Recently, hormonal therapy using abiraterone acetate, a second‐generation
androgen receptor axis‐targeted agent, was reported to improve overall survival and …

Simple Summary The combination of androgen deprivation therapy (ADT) with docetaxel
(DX) or/and with novel anti-androgen receptor therapies have become standards for the …

Molecular tumor volume (MTV) is a parameter of interest in prostate cancer for assessing
total disease burden on prostate-specific membrane antigen (PSMA) PET. Although …

Simple Summary Drug resistance to systematic treatment in genitourinary tumors severely
aggravated the burden on patients and society. Multiple mechanisms were involved in drug …

Purpose Androgen Deprivation Therapy (ADT) is the mainstay treatment in advanced
prostate cancer. We conducted a nationwide population-based study to evaluate the …